help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-1578
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
92/2/673    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singh, V.
Right arrow Articles by Strowski, M. Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singh, V.
Right arrow Articles by Strowski, M. Z.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*(L)-ARGININE
*GLUCAGON
*GLUCOSE
Related Collections
Right arrow Diabetes and Insulin
Right arrow Metabolism
The Journal of Clinical Endocrinology & Metabolism Vol. 92, No. 2 673-680
Copyright © 2007 by The Endocrine Society

Characterization of Somatostatin Receptor Subtype-Specific Regulation of Insulin and Glucagon Secretion: An in Vitro Study on Isolated Human Pancreatic Islets

Vandana Singh, Mathias D. Brendel, Sylvia Zacharias, Stefan Mergler, Henning Jahr, Bertram Wiedenmann, Reinhard G. Bretzel, Ursula Plöckinger and Mathias Z. Strowski

Medizinische Klinik mit Schwerpunkt Hepatologie (V.S., S.Z., S.M., B.W., U.P., M.Z.S.), Gastroenterologie & Interdisziplinäres Stoffwechsel-Centrum: Endokrinologie und Diabetes mellitus, Charité—Universitätsmedizin Berlin, Campus Virchow Klinikum, 13353 Berlin, Germany; and Third Medical Department and Policlinic (M.D.B., H.J., R.G.B.), University Hospital, Justus-Liebig University, Rodthohl 6, 35932 Giessen, Germany

Address all correspondence and requests for reprints to: Mathias Z. Strowski, M.D., Medizinische Klinik m. S. Hepatologie und Gastroenterologie & Interdisziplinäres Stoffwechsel-Centrum: Endokrinologie, Diabetes und Stoffwechsel, Charité—Universitätsmedizin Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany. E-mail: mathias.strowski{at}charite.de.

Introduction: Pancreatic A- and B-cells express somatostatin receptors (SSTRs). Five pharmacologically distinct SSTR subtypes are known (SSTR1–SSTR5). In rodents, SSTR2 inhibits glucagon secretion, whereas SSTR5 suppresses the release of insulin. Human pancreatic A- and B-cells express SSTR1–3 and SSTR5; however, their contribution to the regulation of glucagon and insulin secretion is not well known.

Aim of the Study: The goal of this study was to characterize the role of individual SSTR subtypes in regulating human glucagon and insulin secretion in vitro.

Methods: Human pancreatic islets were isolated from healthy donors and incubated with somatostatin, SSTR1–3-selective and SSTR5-selective agonists, or an SSTR2-selective antagonist (DC-41-33). Stimulation of insulin secretion was induced by glucose (10, 20 mM) alone or in combination with 10 nM exendin-4 or 10 mM L-arginine. Glucagon secretion was induced by 20 mM L-arginine. Basal secretion of insulin and glucagon was measured at 2.8 or 3.3 mM glucose.

Results: SSTR1-, SSTR2-, and SSTR5-selective agonists inhibited insulin secretion with the following order of potency: SSTR2 (EC50, 0.08 nM) > SSTR5 (EC50, 5.3 nM) > SSTR1 (EC50, 35 nM). Glucagon secretion was inhibited by SSTR-selective agonists with the following order of potency: SSTR2 (EC50, 0.05 nM) > SSTR1 (EC50, 1.8 nM) > SSTR5 (EC50, 28 nM). DC-41-33 dose-dependently reversed the effects of the SSTR2-selective agonist on insulin and glucagon secretion.

Conclusion: Our study demonstrates that SSTR2-agonist is the most potent inhibitor of insulin and glucagon secretion from isolated human pancreatic islets. Furthermore, we identify SSTR1- and SSTR5-selective agonists as additional inhibitors of insulin and glucagon secretion from human pancreas.




This article has been cited by other articles:


Home page
EndocrinologyHome page
V. Singh, C. Grotzinger, K. W. Nowak, S. Zacharias, E. Goncz, G. Pless, I. M. Sauer, I. Eichhorn, B. Pfeiffer-Guglielmi, B. Hamprecht, et al.
Somatostatin Receptor Subtype-2-Deficient Mice with Diet-Induced Obesity Have Hyperglycemia, Nonfasting Hyperglucagonemia, and Decreased Hepatic Glycogen Deposition
Endocrinology, August 1, 2007; 148(8): 3887 - 3899.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society